SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical Affairs
July 31 2017 - 8:30AM
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company
focused on the development of drug product candidates to treat
orphan and high-value diseases with unmet parenteral delivery
needs, today announced the appointment of Jeff Myers, M.D., Ph.D.
as Vice President, Medical Affairs.
Dr. Myers, who joins SteadyMed from Gilead
Sciences, will be responsible for all scientific and medical
activities in support of commercializing the Company’s lead drug
product candidate, Trevyent®, which is in development for the
treatment of Pulmonary Arterial Hypertension (PAH). At Gilead, Dr.
Myers was the Senior Medical Director and Global Lead for Gilead’s
cardio-pulmonary products, including Letairis for the treatment of
PAH. Prior to Gilead, Dr. Myers held medical affairs positions at
Genzyme Corporation (now Sanofi Genzyme) as well as various
academic appointments as a cardiothoracic surgeon. Dr. Myers
received his Ph.D. from Georgetown University School of Medicine
and his M.D. from the University of Oklahoma College of Medicine.
He completed fellowships at the University of California, Los
Angeles and Duke University.
“SteadyMed has a track record of attracting
outstanding employees and we are very pleased to welcome Jeff onto
our team. Jeff’s expertise in the cardiovascular space and specific
expertise in the PAH space, in both academia and industry, will be
invaluable to SteadyMed as we seek to bring Trevyent to patients
suffering from PAH,” said Peter Noymer, Ph.D., Executive Vice
President & COO of SteadyMed.
“The recent submission of the New Drug
Application (NDA) for Trevyent marked a major milestone for
SteadyMed, and I am enthused by what the future holds. I look
forward to contributing to the Company’s future success,” added Dr.
Myers.
Designed to address the administration
limitations of existing PAH therapies, Trevyent combines
SteadyMed’s preservative-free, parenteral treprostinil formulation
with the Company’s proprietary PatchPump, a sterile, pre-filled,
pre-programmed, single use disposable infusion system capable of
continuously delivering treprostinil subcutaneously or
intravenously.
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical
company focused on the development of drug products to treat orphan
and high value diseases with unmet parenteral delivery needs. The
company's lead drug product candidate is Trevyent, a development
stage drug product that combines SteadyMed's pre-filled, sterile,
single use, disposable, PatchPump® infusion system, with
treprostinil, a vasodilatory prostacyclin analogue to treat
pulmonary arterial hypertension (PAH). SteadyMed intends to
commercialize Trevyent in the U.S. and has signed an exclusive
license and supply agreement with Cardiome Pharma Corp. for the
commercialization of Trevyent in Europe, Canada and the Middle
East. SteadyMed has offices in San Ramon, California and Rehovot,
Israel. For additional information about SteadyMed please visit
www.steadymed.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, among
others, statements about the company's ability to advance its
development-stage product candidates, including Trevyent.
Forward-looking statements reflect the company's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause
actual results to differ materially. Risks and uncertainties
include, but are not limited to, the risk that Trevyent does not
demonstrate clinical superiority to existing parenteral
treprostinil products, that Trevyent is not approved for
commercialization by the FDA or approval is delayed by patent
litigation, that Trevyent is not granted orphan drug exclusivity,
the risk that drug development involves a lengthy and expensive
process with uncertain outcome, that the company will not satisfy
the milestone and other closing conditions to call the second
tranche of its July 2016 private placement, that the company will
continue to need additional funding, and that the company may be
unable to raise capital when needed, which would force the company
to delay, reduce or eliminate its product candidate development
programs and potentially cease operations. There can be no
assurance that the company will be able to complete the offering on
the terms described herein or in a timely manner, if at all. The
risks, uncertainties and assumptions referred to above are
discussed in detail in our reports filed with the Securities and
Exchange Commission, including our Quarterly Report on Form 10-Q
filed on May 12, 2017. The company does not undertake to publicly
update or revise any forward-looking statements to reflect events
or circumstances that may arise after the date hereof except as may
be required by law.
Contacts:
Marylyn Rigby
Senior Director, Investor Relations and Marketing
925-272-4999
mrigby@steadymed.com
The Ruth Group
Lee Roth
(646) 536-7012
lroth@theruthgroup.com
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
STEADYMED LTD. (NASDAQ:STDY)
Historical Stock Chart
From Apr 2023 to Apr 2024